Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 668 across all filing types
Latest filing 2021-10-12 Major Shareholding Noti…
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-12 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2021, reporting the company's financial results for the quarter ended June 30, 2021. It includes a press release as an exhibit announcing these results. The text explicitly states that the press release is furnished and not filed, and the document is a current report rather than a full quarterly or annual report. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). The document length is 3699 characters, which is short and typical for an earnings release announcement rather than a full interim report. Therefore, the appropriate classification is Earnings Release (ER).
2021-08-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text includes a press release about topline results from a clinical study, furnished as an exhibit. There are no detailed financial statements or comprehensive financial analysis present. The document is relatively short (3555 characters) and primarily serves as a disclosure of a specific event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-07-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a license agreement between Seres Therapeutics and Nestlé. It details the terms of the agreement, including licensing rights, responsibilities, payments, and termination conditions. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The document is an announcement of a significant contract or business arrangement, which fits the category of a Regulatory Filing (RNS) as it does not fall into more specific categories like M&A or Capital/Financing Update. The document length is 8329 characters, which is substantial but the content is focused on the agreement announcement rather than a full report or financial data. Therefore, the best classification is Regulatory Filings (RNS).
2021-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-21 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.